Sherlock Biosciences, Inc.
Newton, MA Part of Orasure Technologies Inc.
- UEI
- Z1K6AV77QHV5
- CAGE
- 8B8D0
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Orasure Technologies Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Bethlehem, PA
Y79RWFLHWDM6
-
Parent
Bethlehem, PA
Y79RWFLHWDM6
- SAM.gov registration date
- Physical address
- 55 Chapel St Suite 100, Newton, MA 02458, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $930,341 |
| FY2025 | $0 |
| FY2024 | $2,148,974 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $930,341 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a low-cost, point-of-need molecular test for flu a+b and self-collected swab specimens. | Office of the Assistant Secretary for Preparedness and Response | $3,079,315 |
Grant awards
Similar vendors
About the company
Sherlock Biosciences, Inc. is a for-profit corporate entity specializing in rapid, field-deployable molecular diagnostics based on CRISPR technology. Registered in SAM.gov since May 1, 2019, the company focuses on developing innovative diagnostic platforms for applications in human health, food security, and biodefense. Their core competency involves creating low-cost, point-of-need molecular testing solutions that can be deployed in various settings, including clinical, agricultural, and field environments, with a particular emphasis on developing tests that are accurate, portable, and accessible.
Through federal contract awards, Sherlock Biosciences has demonstrated expertise in developing advanced molecular diagnostic solutions for critical health challenges. Their most recent significant contract, valued at $9,374,751, was awarded by the Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services. This contract focuses on developing a low-cost, point-of-need molecular test for influenza A and B that can utilize self-collected swab specimens. Previously, the company has received contracts such as an Other Transaction Agreement with the Defense Threat Reduction Agency worth over $2 million, targeting ultra-fast, ultra-sensitive field diagnostic capabilities. These contracts are not typically set aside for specific business types, indicating the company's broad competitive capabilities.
Sherlock Biosciences has secured multiple federal grant awards that underscore its commitment to innovative diagnostic technologies. A notable grant from the National Institute of Allergy and Infectious Diseases provides $298,948 to develop a power-free molecular diagnostic device for detecting sexually transmitted infections, specifically Chlamydia trachomatis and Neisseria gonorrhoeae. Another grant from the Institute of Food Production and Sustainability supports the development of a CRISPR-based diagnostic for White Spot Syndrome Virus in shrimp farming, demonstrating the company's ability to apply its technological platform across different domains. These grants focus on creating diagnostic solutions that are accessible, accurate, and capable of addressing critical screening needs in human health and agricultural settings, with an emphasis on developing technologies that can be used in point-of-need or at-home environments.
Quick answers
Is Sherlock Biosciences, Inc. registered in SAM.gov?
Yes. Sherlock Biosciences, Inc.'s SAM.gov registration is active through January 28, 2027.
How much has Sherlock Biosciences, Inc. received in federal contracts?
Federal contracts obligated $3,079,315 to Sherlock Biosciences, Inc. in fiscal years 2023 through 2027.
How does Sherlock Biosciences, Inc. rank among federal contractors?
Sherlock Biosciences, Inc.'s parent company, Orasure Technologies Inc., ranked #23 in NAICS 62141, #59 in PSC 6550 and #60 in NAICS 325413 in FY2025.
What is Sherlock Biosciences, Inc.'s most recent federal award?
Sherlock Biosciences, Inc.'s most recent federal contract award is Development of a low-cost, point-of-need molecular test for flu a+b and self-collected swab specimens (75A50124C00055), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2024.
On GovTribe
See Sherlock Biosciences, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors